Aurinia Pharmaceuticals Inc. (AUPH) |
|
9.51 -0.06 (-0.63%)
|
03-17 16:00 |
|
Open: |
9.48 |
Pre. Close: |
9.57 |
|
High:
|
9.7799 |
Low:
|
9.36 |
|
Volume:
|
2,483,946 |
Market Cap:
|
1,356(M) |
|
|
|
Technical analysis |
as of: 2023-03-20 8:44:15 AM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 12.18 One year: 14.22 |
| Support: |
Support1: 8.65 Support2: 7.55 |
| Resistance: |
Resistance1: 10.43 Resistance2: 12.18 |
| Pivot: |
9.18  |
| Moving Average: |
MA(5): 9.38 MA(20): 8.9
MA(100): 6.97 MA(250): 8.66  |
| MACD: |
MACD(12,26): 0.3 Signal(9): 0.3 |
| Stochastic oscillator: |
%K(14,3): 63 %D(3): 61.4 |
| RSI: |
RSI(14): 58.9 |
| 52-week: |
High: 13.41 Low: 4.07 |
| Average Vol(K): |
3-Month: 3,187 (K) 10-Days: 3,245 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ AUPH ] has closed below upper band by 28.7%. Bollinger Bands are 36.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
9.79 - 9.84 |
9.84 - 9.87 |
|
Low:
|
9.24 - 9.31 |
9.31 - 9.35 |
|
Close:
|
9.42 - 9.51 |
9.51 - 9.58 |
|
Company Description |
|
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada. |
Headline News |
Sun, 19 Mar 2023
Validea's Top Ten Healthcare Stocks Based On Warren Buffett - 3/19 ... - Nasdaq
Tue, 14 Mar 2023
Aurinia Pharmaceuticals Inc. (AUPH) Stock Observes 15.08% 200 ... - The News Heater
Mon, 13 Mar 2023
Is Aurinia Pharmaceuticals Inc (AUPH) Stock at the Top of the Biotechnology Industry? - InvestorsObserver
Thu, 09 Mar 2023
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q4 2022 Earnings Call Transcript - Yahoo Finance
Wed, 08 Mar 2023
Trade Alert: The Independent Chairman of the Board Of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH), George Milne, Has Just Spent US$178k Buying 40% More Shares - Simply Wall St
Tue, 07 Mar 2023
Will Aurinia Pharmaceuticals Inc (AUPH) Beat the Rest of the Stocks in the Healthcare Sector? - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
143 (M) |
| Shares Float |
140 (M) |
|
% Held by Insiders
|
6.9 (%) |
|
% Held by Institutions
|
38.3 (%) |
|
Shares Short
|
14,960 (K) |
|
Shares Short P.Month
|
11,030 (K) |
Stock Financials |
|
EPS
|
-0.77 |
|
EPS Est Next Qtl
|
-0.11 |
|
EPS Est This Year
|
-1.01 |
|
EPS Est Next Year
|
-0.39 |
|
Book Value (p.s.)
|
2.84 |
|
Profit Margin (%)
|
-80.8 |
|
Operating Margin (%)
|
-83.2 |
|
Return on Assets (ttm)
|
-13.8 |
|
Return on Equity (ttm)
|
-24.5 |
|
Qtrly Rev. Growth
|
21.5 |
|
Gross Profit (p.s.)
|
0.58 |
|
Sales Per Share
|
0.94 |
|
EBITDA (p.s.)
|
-0.77 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-80 (M) |
|
Levered Free Cash Flow
|
-35 (M) |
Stock Valuations |
|
PE Ratio
|
-12.36 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
3.33 |
|
Price to Sales
|
10.11 |
|
Price to Cash Flow
|
-17.05 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
